Bioburden Testing Market is Expected to Witness High Growth Owing to Increasing Adoption of Stringent Regulatory Guidelines

Bioburden Testing Market is Expected to Witness High Growth Owing to Increasing Adoption of Stringent Regulatory Guidelines

during production processes.Stringent regulatory standards imposed by FDA and EMA for bioburden testing have boosted the demand for testing services across pharmaceutical and biotechnology industries. Bioburden testing helps identify any possible microbial contamination early and prevents product recalls. The bioburden testing market deals with testing of non-sterile pharmaceuticals and medical devices to ensure patient safety. Services include aerobic and anaerobic microbial identification as well as enumeration of total viable count.

The Global Bioburden Testing Market is estimated to be valued at US$ 1.40 BN in 2024 and is expected to exhibit a 13% CAGR over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Bioburden Testing Market Size are Charles River Laboratories International, Inc., SGS SA, Merck KGaA, Becton Dickinson and Company, Wuxi Apptec, North American Science Associates Inc., Nelson Laboratories, LLC, Biomérieux SA, Thermo Fisher Scientific and Pacific Biolabs. Charles River Laboratories has a wide range of bioburden testing services and is a leader in the market.

The biomedical sector is expanding globally owing to increasing R&D investments in developing novel biologic drugs and medical devices. This has opened up opportunities for outsourcing of bioburden testing services to meet regulatory guidelines. Many players are focused on expanding their presence in emerging biotech hubs like China, India and Brazil.

Thermo Fisher Scientific acquired microbiology business from Brooks Automation to enhance its product offering with environmental monitoring and bioburden testing systems for controlled environments. Other players are focusing on developing rapid automated microorganism identification systems with low turnaround times to cater to time critical validation requirements better.

Market Drivers

- Stringent regulatory norms imposed by agencies like FDA and EMA have made bioburden testing mandatory at various stages of pharmaceutical and medical device manufacturing. This is a key driver boosting demand.

- Growing biopharmaceutical industry and rising complexity of biologics requiring thorough purity assessment is positively impacting the bioburden testing market.

Market Restrains

- High capital investment requirements for setting up in-house bioburden testing facilities may restrain small companies from opting for insourcing of these services initially.

- Dearth of skilled professionals for advanced microbiological testing negatively impacts the market. Providers face challenges of attracting and retaining microbiologists.

Segment Analysis

The membrane filter method segment currently dominates the bioburden testing market. It is commonly used for testing pharmaceutical and biopharmaceutical products as it provides accurate and reproducible quantification of microorganisms present in samples. It works by filtering microorganisms from a known volume of test solution through a membrane filter. This leaves the microorganisms retained on the surface of the membrane filter which are then enumerated. Membrane filtration is the preferred method in the industry due its ease of use and automation capabilities for high throughput testing.

Global Analysis

The North America region accounts for the largest share of the global bioburden testing market currently. This is mainly attributed to stringent regulations regarding microbial contamination testing mandated by regulatory bodies like FDA for pharmaceutical and medical device products. Further, extensive R&D activities in the pharmaceutical industry and presence of major players in the region also drive the market growth. The Asia Pacific region is projected to witness the fastest growth during the forecast period. This is owing to increasing pharmaceutical manufacturing capacities, growing biotechnology industry and rising outsourcing of bioburden testing services to emerging countries in the region.
​
Get more insights on This Topic- Bioburden Testing Market
Explore More Articles - Carbon Offset Market